Sujita Khanal1, Joongho Joh2, Amy M Kwon3, Maryam Zahin4, Cesar Augusto Perez5, Neal Edward Dunlap6, Craig L Silverman6, Paul Albert Tennant7, Kevin L Potts7, Goetz Haus Kloecker5, Jeffrey Milton Bumpous7, Shin-je Ghim2, Alfred Bennett Jenson4, Rebecca Ann Redman8. 1. Department of Biochemistry and Molecular Genetics, United States; James Graham Brown Cancer Center, United States. 2. James Graham Brown Cancer Center, United States; Division of Medical Oncology/Hematology, Department of Medicine, United States. 3. Data Science for Knowledge Creation Research Center, Department of Statistics, Seoul National University, Seoul, South Korea. 4. James Graham Brown Cancer Center, United States. 5. Division of Medical Oncology/Hematology, Department of Medicine, United States. 6. Department of Radiation Oncology, United States. 7. Division of Otolaryngology, Department of Surgery, University of Louisville School of Medicine, 529 S. Jackson St., Louisville, KY, United States. 8. Division of Medical Oncology/Hematology, Department of Medicine, United States. Electronic address: raredm01@louisville.edu.
Abstract
BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal cancer is associated with improved survival and treatment response as compared to HPV-negative cancers. P16 overexpression is widely accepted as a surrogate marker for HPV positivity. METHODS: A total of 92 serum samples from 75 head and neck squamous cell carcinoma (HNSCC) patients were examined for HPV16 and 18 E7 antibodies by ELISA. Available tissue was tested for HPV-DNA by PCR, and p16 immunohistochemistry was obtained from a deidentified database. RESULTS: Of 75 HNSCC patients, 25 were HPV E7 seropositive. Seropositivity was strongly associated with cancers of the oropharynx, and correlated with positive p16 immunohistochemistry (IHC) and HPV-DNA. Post-treatment serum was available in a limited subset of patients, revealing a decrease in antibody titers following response to treatment. CONCLUSIONS: HPV E7 seropositivity correlated with positive tumor HPV-DNA and p16 expression, and was strongly associated with cancers of the oropharynx. E7 serology warrants further study as a potential biomarker in HPV-positive HNSCC.
BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal cancer is associated with improved survival and treatment response as compared to HPV-negative cancers. P16 overexpression is widely accepted as a surrogate marker for HPV positivity. METHODS: A total of 92 serum samples from 75 head and neck squamous cell carcinoma (HNSCC) patients were examined for HPV16 and 18 E7 antibodies by ELISA. Available tissue was tested for HPV-DNA by PCR, and p16 immunohistochemistry was obtained from a deidentified database. RESULTS: Of 75 HNSCC patients, 25 were HPV E7 seropositive. Seropositivity was strongly associated with cancers of the oropharynx, and correlated with positive p16 immunohistochemistry (IHC) and HPV-DNA. Post-treatment serum was available in a limited subset of patients, revealing a decrease in antibody titers following response to treatment. CONCLUSIONS:HPV E7 seropositivity correlated with positive tumorHPV-DNA and p16 expression, and was strongly associated with cancers of the oropharynx. E7 serology warrants further study as a potential biomarker in HPV-positive HNSCC.
Authors: Karen S Anderson; Garrick Wallstrom; Hilde Langseth; Marshall Posner; Julia N Cheng; Rizwan Alam; Diego Chowell; Ingegerd E Furre; Jon Mork Journal: Oral Oncol Date: 2017-09-01 Impact factor: 5.337